Sp483
THE ENIGMA OF LGD: IS IT THE REAL DEAL?
Date
May 7, 2023
Explore related products in the following collection:
Society: ASGE
Presenter
Tracks
Related Products
LIMITED RISK OF RESIDUAL CANCER AFTER ENDOSCOPIC RESECTION OF EARLY BARRETT'S NEOPLASIA WITH CONFIRMED VERTICAL R1 MARGIN: A NATIONWIDE COHORT IN THE NETHERLANDS
Current guidelines advise esophagectomy for submucosal esophageal adenocarcinoma (T1b EAC). However, data from retrospective studies suggest that endoscopic follow-up (FU) may be a valid alternative in patients without signs of lymph node metastases (LNM) at baseline…
PLACEHOLDER
SOCIETY: ASGE
ENDOSCOPIC FOLLOW-UP OF RADICALLY RESECTED SUBMUCOSAL ADENOCARCINOMA IN BARRETT’S ESOPHAGUS: INTERIM RESULTS OF AN ONGOING PROSPECTIVE, INTERNATIONAL, MULTICENTER COHORT REGISTRY (PREFER TRIAL)
Current guidelines advise esophagectomy for submucosal esophageal adenocarcinoma (T1b EAC). However, data from retrospective studies suggest that endoscopic follow-up (FU) may be a valid alternative in patients without signs of lymph node metastases (LNM) at baseline…
VIDEO-BASED COMPUTER AIDED DETECTION SYSTEM DETECTS BARRETT’S NEOPLASIA WITH HIGH ACCURACY DURING LIVE ENDOSCOPIC PROCEDURES: A MULTI-CENTER PILOT AND FEASIBILITY STUDY
BACKGROUND: Using EsoCheck (EC), a non-endoscopic balloon device for sampling the distal esophagus, coupled with EsoGuard (EG), a DNA based testing screening for Barrett’s esophagus (BE), we have previously reported high sensitivity and specificity for detection of BE among patients with known BE c…
